Published in Anal Bioanal Chem on March 29, 2011
Identification of human plasma metabolites exhibiting time-of-day variation using an untargeted liquid chromatography-mass spectrometry metabolomic approach. Chronobiol Int (2012) 1.00
Leptin reverts pro-apoptotic and antiproliferative effects of α-linolenic acids in BCR-ABL positive leukemic cells: involvement of PI3K pathway. PLoS One (2011) 0.83
The role of group IIF-secreted phospholipase A2 in epidermal homeostasis and hyperplasia. J Exp Med (2015) 0.81
Effect of surfactant hydrophobicity on the pathway for unfolding of ubiquitin. J Am Chem Soc (2012) 0.77
Systematic Review of the Association between Lipoprotein-Associated Phospholipase A2 and Atherosclerosis. N Am J Med Sci (Boston) (2011) 0.76
In vitro anti-Plasmodium falciparum properties of the full set of human secreted phospholipases A2. Infect Immun (2015) 0.75
Inflammation in atherosclerosis. Nature (2002) 28.92
The pathogenesis of atherosclerosis: a perspective for the 1990s. Nature (1993) 27.07
Beyond cholesterol. Modifications of low-density lipoprotein that increase its atherogenicity. N Engl J Med (1989) 15.67
Lipoprotein metabolism in the macrophage: implications for cholesterol deposition in atherosclerosis. Annu Rev Biochem (1983) 7.70
Minimally modified low density lipoprotein induces monocyte chemotactic protein 1 in human endothelial cells and smooth muscle cells. Proc Natl Acad Sci U S A (1990) 4.34
Biochemistry and physiology of mammalian secreted phospholipases A2. Annu Rev Biochem (2008) 2.94
The secretory phospholipase A2 gene is a candidate for the Mom1 locus, a major modifier of ApcMin-induced intestinal neoplasia. Cell (1995) 2.89
Lysophosphatidylcholine: a chemotactic factor for human monocytes and its potential role in atherogenesis. Proc Natl Acad Sci U S A (1988) 2.83
Identification of 5-lipoxygenase as a major gene contributing to atherosclerosis susceptibility in mice. Circ Res (2002) 2.69
Disruption of the 12/15-lipoxygenase gene diminishes atherosclerosis in apo E-deficient mice. J Clin Invest (1999) 2.54
Lysophosphatidylcholine, a component of atherogenic lipoproteins, induces mononuclear leukocyte adhesion molecules in cultured human and rabbit arterial endothelial cells. J Clin Invest (1992) 2.45
Roles of thromboxane A(2) and prostacyclin in the development of atherosclerosis in apoE-deficient mice. J Clin Invest (2004) 2.12
Subtype-selective antagonists of lysophosphatidic Acid receptors inhibit platelet activation triggered by the lipid core of atherosclerotic plaques. Circulation (2003) 2.07
Structure-based design of the first potent and selective inhibitor of human non-pancreatic secretory phospholipase A2. Nat Struct Biol (1995) 1.96
A randomized, double-blinded, placebo-controlled clinical trial of LY333013, a selective inhibitor of group II secretory phospholipase A2, in the treatment of rheumatoid arthritis. J Rheumatol (2005) 1.95
Group v secretory phospholipase A2 promotes atherosclerosis: evidence from genetically altered mice. Arterioscler Thromb Vasc Biol (2007) 1.89
Effects of 1-H-indole-3-glyoxamide (A-002) on concentration of secretory phospholipase A2 (PLASMA study): a phase II double-blind, randomised, placebo-controlled trial. Lancet (2009) 1.87
Lysophosphatidic acid induces neointima formation through PPARgamma activation. J Exp Med (2004) 1.86
Metabolism and atherogenic disease association of lysophosphatidylcholine. Atherosclerosis (2009) 1.71
Lipolysis of LDL by human secretory phospholipase A(2) induces particle fusion and enhances the retention of LDL to human aortic proteoglycans. Arterioscler Thromb Vasc Biol (2001) 1.66
Secretory phospholipase A2 group V: lesion distribution, activation by arterial proteoglycans, and induction in aorta by a Western diet. Arterioscler Thromb Vasc Biol (2006) 1.60
Deletion of microsomal prostaglandin E synthase-1 augments prostacyclin and retards atherogenesis. Proc Natl Acad Sci U S A (2006) 1.52
Molecular basis for the association of group IIA phospholipase A(2) and decorin in human atherosclerotic lesions. Circ Res (2000) 1.51
Circulating levels of secretory type II phospholipase A(2) predict coronary events in patients with coronary artery disease. Circulation (1999) 1.50
Group X secretory phospholipase A(2) augments angiotensin II-induced inflammatory responses and abdominal aortic aneurysm formation in apoE-deficient mice. Atherosclerosis (2010) 1.48
Role of group II secretory phospholipase A2 in atherosclerosis: 1. Increased atherogenesis and altered lipoproteins in transgenic mice expressing group IIa phospholipase A2. Arterioscler Thromb Vasc Biol (1999) 1.46
Focused lipidomics by tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci (2005) 1.38
Minimally oxidized low-density lipoprotein increases expression of scavenger receptor A, CD36, and macrosialin in resident mouse peritoneal macrophages. Arterioscler Thromb Vasc Biol (1998) 1.31
Circulating secretory phospholipase A2 activity predicts recurrent events in patients with severe acute coronary syndromes. J Am Coll Cardiol (2005) 1.28
Cloning, chromosomal mapping, and expression of a novel human secretory phospholipase A2. J Biol Chem (1997) 1.28
Accelerated glucose intolerance, nephropathy, and atherosclerosis in prostaglandin D2 synthase knock-out mice. J Biol Chem (2005) 1.26
Transgenic expression of group V, but not group X, secreted phospholipase A2 in mice leads to neonatal lethality because of lung dysfunction. J Biol Chem (2006) 1.25
Phospholipase A(2) in vascular disease. Circ Res (2001) 1.23
Potent modification of low density lipoprotein by group X secretory phospholipase A2 is linked to macrophage foam cell formation. J Biol Chem (2002) 1.22
Lysophosphatidylcholine regulates human microvascular endothelial cell expression of chemokines. J Mol Cell Cardiol (2003) 1.20
Analyses of group III secreted phospholipase A2 transgenic mice reveal potential participation of this enzyme in plasma lipoprotein modification, macrophage foam cell formation, and atherosclerosis. J Biol Chem (2008) 1.19
Group V sPLA2 hydrolysis of low-density lipoprotein results in spontaneous particle aggregation and promotes macrophage foam cell formation. Arterioscler Thromb Vasc Biol (2004) 1.18
Distinct mechanisms for OxLDL uptake and cellular trafficking by class B scavenger receptors CD36 and SR-BI. J Lipid Res (2007) 1.15
A novel anti-inflammatory role for secretory phospholipase A2 in immune complex-mediated arthritis. EMBO Mol Med (2010) 1.13
Rapid and selective identification of molecular species in phosphatidylcholine and sphingomyelin by conditional neutral loss scanning and MS3. Rapid Commun Mass Spectrom (2004) 1.13
Emerging roles of secreted phospholipase A2 enzymes: Lessons from transgenic and knockout mice. Biochimie (2010) 1.10
Macrophage secretory phospholipase A2 group X enhances anti-inflammatory responses, promotes lipid accumulation, and contributes to aberrant lung pathology. J Biol Chem (2008) 1.08
Expression of secretory phospholipase A2s in human atherosclerosis development. Atherosclerosis (2007) 1.07
Differential hydrolysis of molecular species of lipoprotein phosphatidylcholine by groups IIA, V and X secretory phospholipases A2. Biochim Biophys Acta (2005) 1.06
Group V secretory phospholipase A2-modified low density lipoprotein promotes foam cell formation by a SR-A- and CD36-independent process that involves cellular proteoglycans. J Biol Chem (2005) 1.06
Role of group IIa and group V secretory phospholipases A(2) in the metabolism of lipoproteins. Substrate specificities of the enzymes and the regulation of their activities by sphingomyelin. Biochemistry (2002) 1.03
Varespladib (A-002), a secretory phospholipase A2 inhibitor, reduces atherosclerosis and aneurysm formation in ApoE-/- mice. J Cardiovasc Pharmacol (2009) 1.03
Lipoproteins are substrates for human secretory group IIA phospholipase A2: preferential hydrolysis of acute phase HDL. J Lipid Res (1998) 1.01
Large scale gene expression analysis of cholesterol-loaded macrophages. J Biol Chem (2000) 1.00
Secretory phospholipase A2 enzymes in atherogenesis. Curr Opin Lipidol (2005) 0.98
Macrophage-expressed group IIA secretory phospholipase A2 increases atherosclerotic lesion formation in LDL receptor-deficient mice. Arterioscler Thromb Vasc Biol (2003) 0.97
Atherogenic properties of LDL particles modified by human group X secreted phospholipase A2 on human endothelial cell function. FASEB J (2006) 0.97
Tagging SNP haplotype analysis of the secretory PLA2-V gene, PLA2G5, shows strong association with LDL and oxLDL levels, suggesting functional distinction from sPLA2-IIA: results from the UDACS study. Hum Mol Genet (2007) 0.96
Neuronal expression and neuritogenic action of group X secreted phospholipase A2. J Biol Chem (2005) 0.95
New phospholipase A(2) isozymes with a potential role in atherosclerosis. Curr Opin Lipidol (2003) 0.95
Localization of nonpancreatic secretory phospholipase A2 in normal and atherosclerotic arteries. Activity of the isolated enzyme on low-density lipoproteins. Arterioscler Thromb Vasc Biol (1997) 0.94
Secretory phospholipase A2-IID is an effector molecule of CD4+CD25+ regulatory T cells. Proc Natl Acad Sci U S A (2009) 0.93
The synergistic inhibition of atherogenesis in apoE-/- mice between pravastatin and the sPLA2 inhibitor varespladib (A-002). J Lipid Res (2008) 0.92
The capacity of group V sPLA2 to increase atherogenicity of ApoE-/- and LDLR-/- mouse LDL in vitro predicts its atherogenic role in vivo. Arterioscler Thromb Vasc Biol (2009) 0.91
Group III secreted phospholipase A2 transgenic mice spontaneously develop inflammation. Biochem J (2009) 0.91
Indole inhibitors of human nonpancreatic secretory phospholipase A2. 1. Indole-3-acetamides. J Med Chem (1996) 0.90
Group V and X secretory phospholipase A(2)s-induced modification of high-density lipoprotein linked to the reduction of its antiatherogenic functions. Biochim Biophys Acta (2003) 0.88
Binding of human phospholipase A2 type II to proteoglycans. Differential effect of glycosaminoglycans on enzyme activity. J Biol Chem (1996) 0.86
Phospholipase A2-modified low-density lipoprotein activates macrophage peroxisome proliferator-activated receptors. Arterioscler Thromb Vasc Biol (2009) 0.85
Ultrastructural localization of secretory type II phospholipase A2 in atherosclerotic and nonatherosclerotic regions of human arteries. Arterioscler Thromb Vasc Biol (1998) 0.84
Group X secretory phospholipase A2 negatively regulates ABCA1 and ABCG1 expression and cholesterol efflux in macrophages. Arterioscler Thromb Vasc Biol (2010) 0.84
Hydrolysis of minor glycerophospholipids of plasma lipoproteins by human group IIA, V and X secretory phospholipases A2. Biochim Biophys Acta (2006) 0.83
Minimal oxidation and storage of low density lipoproteins result in an increased susceptibility to phospholipid hydrolysis by phospholipase A2. Atherosclerosis (1997) 0.83
Bioactive products generated by group V sPLA(2) hydrolysis of LDL activate macrophages to secrete pro-inflammatory cytokines. Cytokine (2010) 0.82
Increased lipolysis by secretory phospholipase A(2) group V of lipoproteins in diabetic dyslipidaemia. J Intern Med (2008) 0.82
Physiological roles of group X-secreted phospholipase A2 in reproduction, gastrointestinal phospholipid digestion, and neuronal function. J Biol Chem (2011) 0.80
Varespladib methyl, an oral phospholipase A2 inhibitor for the potential treatment of coronary artery disease. IDrugs (2009) 0.78
Molecular and functional characterization of polymorphisms in the secreted phospholipase A2 group X gene: relevance to coronary artery disease. J Mol Med (Berl) (2009) 0.78
Secretory PLA2 inhibitor indoxam suppresses LDL modification and associated inflammatory responses in TNFalpha-stimulated human endothelial cells. Br J Pharmacol (2008) 0.78
Inflammation and atherosclerosis: Group IIa and Group V sPLA2 are not redundant. Arterioscler Thromb Vasc Biol (2006) 0.77
The lipid mediator protectin D1 inhibits influenza virus replication and improves severe influenza. Cell (2013) 3.19
Phospholipase A2 enzymes. Prostaglandins Other Lipid Mediat (2002) 2.92
Recent progress in phospholipase A₂ research: from cells to animals to humans. Prog Lipid Res (2010) 2.17
Reduced pain hypersensitivity and inflammation in mice lacking microsomal prostaglandin e synthase-1. J Biol Chem (2004) 1.65
2,2-[(E)-3,3-Diphenyl-prop-2-ene-1,1-di-yl]bis-(3-hy-droxy-cyclo-hex-2-en-1-one). Acta Crystallogr Sect E Struct Rep Online (2011) 1.56
Secreted phospholipase A2 revisited. J Biochem (2011) 1.52
Potential role of microsomal prostaglandin E synthase-1 in tumorigenesis. J Biol Chem (2003) 1.47
Cerebral small vessel disease and chronic kidney disease (CKD): results of a cross-sectional study in community-based Japanese elderly. J Neurol Sci (2008) 1.46
Mast cells mediate neutrophil recruitment and vascular leakage through the NLRP3 inflammasome in histamine-independent urticaria. J Exp Med (2009) 1.36
Ethane-1,2-diyl bis-(benzene-dithio-ate). Acta Crystallogr Sect E Struct Rep Online (2011) 1.29
2,2'-[(E)-3-(4-Nitro-phen-yl)prop-2-ene-1,1-di-yl]bis-(3-hy-droxy-5,5-dimethyl-cyclo-hex-2-en-1-one). Acta Crystallogr Sect E Struct Rep Online (2012) 1.28
RalA functions as an indispensable signal mediator for the nutrient-sensing system. J Biol Chem (2008) 1.28
Characterization of enteropathogenic and enteroaggregative Escherichia coli isolated from diarrheal outbreaks. J Clin Microbiol (2002) 1.25
Transgenic expression of group V, but not group X, secreted phospholipase A2 in mice leads to neonatal lethality because of lung dysfunction. J Biol Chem (2006) 1.25
Biosynthesis of anandamide and N-palmitoylethanolamine by sequential actions of phospholipase A2 and lysophospholipase D. Biochem J (2004) 1.25
Coupling between cyclooxygenases and terminal prostanoid synthases. Biochem Biophys Res Commun (2005) 1.22
Prostaglandin E synthase, a terminal enzyme for prostaglandin E2 biosynthesis. J Biochem Mol Biol (2005) 1.21
Critical role of PICT-1, a tumor suppressor candidate, in phosphatidylinositol 3,4,5-trisphosphate signals and tumorigenic transformation. Mol Biol Cell (2006) 1.21
Analyses of group III secreted phospholipase A2 transgenic mice reveal potential participation of this enzyme in plasma lipoprotein modification, macrophage foam cell formation, and atherosclerosis. J Biol Chem (2008) 1.19
Prostaglandin E synthases: Understanding their pathophysiological roles through mouse genetic models. Biochimie (2010) 1.14
Emerging roles of secreted phospholipase A2 enzymes: Lessons from transgenic and knockout mice. Biochimie (2010) 1.10
Apparent diffusion coefficient in pancreatic cancer: characterization and histopathological correlations. J Magn Reson Imaging (2008) 1.08
Transcriptional regulation of the membrane-associated prostaglandin E2 synthase gene. Essential role of the transcription factor Egr-1. J Biol Chem (2002) 1.08
Lymphoid tissue phospholipase A2 group IID resolves contact hypersensitivity by driving antiinflammatory lipid mediators. J Exp Med (2013) 1.08
Diverse cellular localizations of secretory phospholipase A2 enzymes in several human tissues. Biochim Biophys Acta (2005) 1.08
Phosphorylated alpha-synuclein at Ser-129 is targeted to the proteasome pathway in a ubiquitin-independent manner. J Biol Chem (2010) 1.07
Expression of secretory phospholipase A2s in human atherosclerosis development. Atherosclerosis (2007) 1.07
Mast cell maturation is driven via a group III phospholipase A2-prostaglandin D2-DP1 receptor paracrine axis. Nat Immunol (2013) 1.06
Group III secreted phospholipase A2 regulates epididymal sperm maturation and fertility in mice. J Clin Invest (2010) 1.06
Rat islet culture in serum-free medium containing silk protein sericin. J Hepatobiliary Pancreat Surg (2009) 1.03
Small RNA transcriptomes of two types of exosomes in human whole saliva determined by next generation sequencing. Biol Pharm Bull (2013) 1.03
Emodin, a naturally occurring anthraquinone derivative, suppresses IgE-mediated anaphylactic reaction and mast cell activation. Biochem Pharmacol (2011) 1.01
Expression of secretory phospholipase A2 enzymes in lungs of humans with pneumonia and their potential prostaglandin-synthetic function in human lung-derived cells. Biochem J (2005) 1.00
Induction of distinct sets of secretory phospholipase A(2) in rodents during inflammation. Biochim Biophys Acta (2003) 1.00
Group X phospholipase A2 is released during sperm acrosome reaction and controls fertility outcome in mice. J Clin Invest (2010) 0.96
Impaired mast cell maturation and degranulation and attenuated allergic responses in Ndrg1-deficient mice. J Immunol (2007) 0.96
Regulation of cytosolic prostaglandin E synthase by phosphorylation. Biochem J (2004) 0.96
Neuronal expression and neuritogenic action of group X secreted phospholipase A2. J Biol Chem (2005) 0.95
Regulation of cytosolic prostaglandin E2 synthase by 90-kDa heat shock protein. Biochem Biophys Res Commun (2003) 0.95
Identification of NDRG1 as an early inducible gene during in vitro maturation of cultured mast cells. Biochem Biophys Res Commun (2003) 0.94
N-terminal region of alpha-synuclein is essential for the fatty acid-induced oligomerization of the molecules. FEBS Lett (2008) 0.94
Microsomal prostaglandin E synthase-1 in both cancer cells and hosts contributes to tumour growth, invasion and metastasis. Biochem J (2009) 0.93
Various secretory phospholipase A2 enzymes are expressed in rheumatoid arthritis and augment prostaglandin production in cultured synovial cells. FEBS J (2005) 0.93
Redox-responsive molecular helices with highly condensed π-clouds. Nat Chem (2010) 0.92
Search of factors that intermediate cytokine-induced group IIA phospholipase A2 expression through the cytosolic phospholipase A2- and 12/15-lipoxygenase-dependent pathway. J Biol Chem (2005) 0.92
Localization of various secretory phospholipase A2 enzymes in male reproductive organs. Biochim Biophys Acta (2004) 0.91
Effect of the silk protein sericin on cryopreserved rat islets. J Hepatobiliary Pancreat Sci (2012) 0.91
Group III secreted phospholipase A2 transgenic mice spontaneously develop inflammation. Biochem J (2009) 0.91
Stabilization of mast cells by heme oxygenase-1: an anti-inflammatory role. Am J Physiol Heart Circ Physiol (2002) 0.90
m-Calpain induction in vascular endothelial cells on human and mouse atheromas and its roles in VE-cadherin disorganization and atherosclerosis. Circulation (2011) 0.90
Mechanical stimulation and solid seeding trigger single-crystal-to-single-crystal molecular domino transformations. Nat Commun (2013) 0.90
PGD2 induces eotaxin-3 via PPARγ from sebocytes: a possible pathogenesis of eosinophilic pustular folliculitis. J Allergy Clin Immunol (2011) 0.89
Lysophosphatidylcholine acyltransferase 1 altered phospholipid composition and regulated hepatoma progression. J Hepatol (2013) 0.89
Serine 129 phosphorylation of membrane-associated α-synuclein modulates dopamine transporter function in a G protein-coupled receptor kinase-dependent manner. Mol Biol Cell (2013) 0.87
Contribution of endogenous G-protein-coupled receptor kinases to Ser129 phosphorylation of alpha-synuclein in HEK293 cells. Biochem Biophys Res Commun (2009) 0.86
Deficiency of phospholipase A2 receptor exacerbates ovalbumin-induced lung inflammation. J Immunol (2013) 0.85
Characterization of cytochrome P450 expression in murine embryonic stem cell-derived hepatic tissue system. Drug Metab Dispos (2006) 0.85
Human group III secreted phospholipase A2 promotes neuronal outgrowth and survival. Biochem J (2008) 0.85
Human group III phospholipase A2 suppresses adenovirus infection into host cells. Evidence that group III, V and X phospholipase A2s act on distinct cellular phospholipid molecular species. Biochim Biophys Acta (2007) 0.85
Group V and X secretory phospholipase A2 prevents adenoviral infection in mammalian cells. Biochem J (2006) 0.85
Strain differences in hepatic cytochrome P450 1A and 3A expression between Sprague-Dawley and Wistar rats. J Toxicol Sci (2008) 0.84
Revascularization and function of pancreatic islet isografts in diabetic rats following transplantation. Cell Transplant (2003) 0.84
Group X secreted phospholipase A2 limits the development of atherosclerosis in LDL receptor-null mice. Arterioscler Thromb Vasc Biol (2013) 0.84
Induction of PYPAF1 during in vitro maturation of mouse mast cells. J Biochem (2003) 0.84
Ruptured mucinous cystic neoplasm with an associated invasive carcinoma of pancreatic head in a pregnant woman: report of a case and review of literature. Pathol Int (2010) 0.84
Coupling between cyclooxygenases and prostaglandin F(2alpha) synthase. Detection of an inducible, glutathione-activated, membrane-bound prostaglandin F(2alpha)-synthetic activity. Biochim Biophys Acta (2003) 0.84
Establishment of the culture model system that reflects the process of terminal differentiation of connective tissue-type mast cells. FEBS Lett (2008) 0.84
Mitochondrial dysfunction and reduced prostaglandin synthesis in skeletal muscle of Group VIB Ca2+-independent phospholipase A2gamma-deficient mice. J Lipid Res (2010) 0.84
Distinct responses to mechanical grinding and hydrostatic pressure in luminescent chromism of tetrathiazolylthiophene. J Am Chem Soc (2013) 0.84
Prostaglandin E2-EP3 signaling induces inflammatory swelling by mast cell activation. J Immunol (2013) 0.83
Lack of phospholipase A2 receptor increases susceptibility to cardiac rupture after myocardial infarction. Circ Res (2013) 0.83
Smad3 and Snail show circadian expression in human gingival fibroblasts, human mesenchymal stem cell, and in mouse liver. Biochem Biophys Res Commun (2012) 0.83
A novel role of group VIB calcium-independent phospholipase A2 (iPLA2gamma) in the inducible expression of group IIA secretory PLA2 in rat fibroblastic cells. J Biol Chem (2007) 0.83
Change in prostaglandin E synthases (PGESs) in microsomal PGES-1 knockout mice in a preterm delivery model. J Endocrinol (2005) 0.83
Hair follicular expression and function of group X secreted phospholipase A2 in mouse skin. J Biol Chem (2011) 0.83
V-shaped organic semiconductors with solution processability, high mobility, and high thermal durability. Adv Mater (2013) 0.83